Explore RLT services
Our all-encompassing service aims to simplify the RLT journey and minimise time-to-treatment for your eligible patients.
Prescribing information (external link)
Image
Image
Pluvicto®▼ (lutetium [177Lu] vipivotide tetraxetan) resources
Pluvicto is indicated for the treatment of adult patients with:1
Prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have progressed on or after treatment with androgen receptor pathway inhibitor (ARPI) therapy and are considered appropriate to delay taxane-based chemotherapy
PSMA-positive mCRPC who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes
Pluvicto is available in the United Kingdom to eligible private patients.
Resources for patients
To be shared with adult patients in the UK who have been prescribed Pluvicto for their PSMA-positive mCRPC or for whom the prescribing decision has been made.
The resources do not replace the Patient Information Leaflet (PIL) that comes with Pluvicto or advice from the patient’s healthcare team.
To access the PIL for Pluvicto patients in the UK, please visit the electronic medicines compendium (emc) website.
Image
Image
177Lu, lutetium-177; AR, androgen receptor; ARPI, androgen receptor pathway inhibitor; mCRPC, metastatic castration-resistant prostate cancer; PIL, patient information leaflet; PSMA, prostate-specific membrane antigen; RLT, radioligand therapy.
Reference
Pluvicto®▼ (lutetium [177Lu] vipivotide tetraxetan) Summary of Product Characteristics.
UK | February 2026 | FA-11470230-1
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
